Pharmacokinetic and pharmacodynamic drug–drug interactions: research methods and applications
L Sun, K Mi, Y Hou, T Hui, L Zhang, Y Tao, Z Liu… - Metabolites, 2023 - mdpi.com
Because of the high research and development cost of new drugs, the long development
process of new drugs, and the high failure rate at later stages, combining past drugs has …
process of new drugs, and the high failure rate at later stages, combining past drugs has …
Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?
JD Gomez-Mantilla, F Huang, SA Peters - Clinical Pharmacokinetics, 2023 - Springer
Abstract Background and Objective Mechanistic static and dynamic physiologically based
pharmacokinetic models are used in clinical drug development to assess the risk of drug …
pharmacokinetic models are used in clinical drug development to assess the risk of drug …
Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in …
S Bansal, MF Paine, JD Unadkat - Drug Metabolism and Disposition, 2022 - ASPET
We previously reported the unbound reversible (IC50, u) and time-dependent (KI, u)
inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC …
inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC …
Prediction of CYP‐mediated DDIs involving inhibition: approaches to address the requirements for system qualification of the Simcyp simulator
PJ Kilford, KF Chen, K Crewe, I Gardner… - CPT …, 2022 - Wiley Online Library
Physiologically‐based pharmacokinetic (PBPK) modeling is being increasingly used in drug
development to avoid unnecessary clinical drug–drug interaction (DDI) studies and inform …
development to avoid unnecessary clinical drug–drug interaction (DDI) studies and inform …
Discovery of the potent and selective MC4R antagonist PF-07258669 for the potential treatment of appetite loss
MR Garnsey, AC Smith, J Polivkova… - Journal of Medicinal …, 2023 - ACS Publications
The melanocortin-4 receptor (MC4R) is a centrally expressed, class A GPCR that plays a
key role in the regulation of appetite and food intake. Deficiencies in MC4R signaling result …
key role in the regulation of appetite and food intake. Deficiencies in MC4R signaling result …
Projections of Drug-Drug Interactions Caused by Time-Dependent Inhibitors of Cytochrome P450 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 Using In Vitro Data in Static and …
E Tseng, J Lin, TJ Strelevitz, E DaSilva… - Drug Metabolism and …, 2024 - ASPET
In vitro time-dependent inhibition (TDI) kinetic parameters for cytochrome P450 (P450) 1A2,
2B6, 2C8, 2C9, 2C19, and 2D6 were determined in pooled human liver microsomes for 19 …
2B6, 2C8, 2C9, 2C19, and 2D6 were determined in pooled human liver microsomes for 19 …
Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes
LWT Tang, E DaSilva, K Lapham, RS Obach - Drug Metabolism and …, 2024 - ASPET
Aldehyde oxidase (AO) is a molybdenum cofactor-containing cytosolic enzyme that has
gained prominence due to its involvement in the developmental failure of several drug …
gained prominence due to its involvement in the developmental failure of several drug …
Predictive in vitro-in vivo extrapolation for time dependent inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 using pooled human hepatocytes …
D Ramsden, ES Perloff, A Whitcher-Johnstone… - Drug Metabolism and …, 2022 - ASPET
Inactivation of Cytochrome P450 (CYP450) enzymes can lead to significant increases in
exposure of comedicants. The majority of reported in vitro to in vivo extrapolation (IVIVE) …
exposure of comedicants. The majority of reported in vitro to in vivo extrapolation (IVIVE) …
Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform …
DJ Mulford, D Ramsden, L Zhang… - CPT …, 2023 - Wiley Online Library
Vonoprazan is metabolized extensively through CYP3A and is an in vitro time‐dependent
inhibitor of CYP3A. A tiered approach was applied to understand the CYP3A victim and …
inhibitor of CYP3A. A tiered approach was applied to understand the CYP3A victim and …
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2 (−)/(+) populations
C Steinbronn, YS Chhonker, J Stewart… - Clinical and …, 2023 - Wiley Online Library
Hydroxychloroquine (HCQ) is Food and Drug Administration (FDA)‐approved for malaria,
systemic and chronic discoid lupus erythematosus, and rheumatoid arthritis. Because HCQ …
systemic and chronic discoid lupus erythematosus, and rheumatoid arthritis. Because HCQ …